4.30
Cogent Biosciences Inc stock is traded at $4.30, with a volume of 957.07K.
It is down -1.60% in the last 24 hours and down -39.94% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$4.37
Open:
$4.29
24h Volume:
957.07K
Relative Volume:
0.68
Market Cap:
$521.43M
Revenue:
-
Net Income/Loss:
$-242.30M
P/E Ratio:
-1.7339
EPS:
-2.48
Net Cash Flow:
$-192.10M
1W Performance:
-6.11%
1M Performance:
-39.94%
6M Performance:
-63.74%
1Y Performance:
-35.92%
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
COGT
Cogent Biosciences Inc
|
4.30 | 521.43M | 0 | -242.30M | -192.10M | -2.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Dec-11-24 | Downgrade | Needham | Buy → Hold |
Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Feb-08-24 | Initiated | Citigroup | Buy |
Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
Dec-08-23 | Initiated | JP Morgan | Overweight |
Apr-28-23 | Initiated | Robert W. Baird | Outperform |
Mar-27-23 | Resumed | H.C. Wainwright | Buy |
Dec-14-22 | Initiated | Needham | Buy |
Jun-28-22 | Initiated | Guggenheim | Buy |
Oct-11-21 | Initiated | H.C. Wainwright | Buy |
Jun-09-21 | Resumed | Jefferies | Buy |
Dec-23-20 | Initiated | Piper Sandler | Overweight |
Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences Inc (COGT) Becoming More Attractive for Investors - knoxdaily.com
(COGT) Technical Data - news.stocktradersdaily.com
Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts - Insider Monkey
Geode Capital Management LLC Boosts Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Vanguard Group Inc. Purchases 418,975 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Wellington Management Group LLP Trims Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
KLP Kapitalforvaltning AS Takes $88,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Corebridge Financial Inc. - Defense World
Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement - Seeking Alpha
Cogent Biosciences stock hits 52-week low at $4.24 By Investing.com - Investing.com South Africa
Cogent Biosciences stock hits 52-week low at $4.24 - Investing.com
Trend Tracker for (COGT) - news.stocktradersdaily.com
Teacher Retirement System of Texas Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.43 Consensus PT from Brokerages - Defense World
When Would Be The Best Time To Buy Cogent Biosciences Inc (NASDAQ: COGT) Stock? - stocksregister.com
21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP - Defense World
Swiss National Bank Sells 3,000 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo
Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire
Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan
Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - TradingView
Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Insider Monkey
Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR
Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter
Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World
Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times
Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks
New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
When the Price of (COGT) Talks, People Listen - Stock Traders Daily
Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks
Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for COGT - The AM Reporter
Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire
Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq
Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):